Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Treating Acute MI Patients With Aggrastat on Their Way to Hospital

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2009 by The Baruch Padeh Medical Center, Poriya.
Recruitment status was:  Recruiting
Sponsor:
Information provided by:
The Baruch Padeh Medical Center, Poriya
ClinicalTrials.gov Identifier:
NCT00300833
First received: March 1, 2006
Last updated: August 10, 2011
Last verified: January 2009
  Purpose
Treating an AMI patient with ST elevation with Aggrastat in the ambulance on his or her way to the hospital.

Condition Intervention Phase
Acute Myocardial Infarction
Drug: Tirofiban
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by The Baruch Padeh Medical Center, Poriya:

Primary Outcome Measures:
  • mortality [ Time Frame: immidiately ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • TIMI flow [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
    feeling better


Estimated Enrollment: 200
Study Start Date: January 2006
Estimated Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Tirofiban
    pci
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

patients with acute Myocardial infarction with ST elevation , and moving by ambulance to Poriya hospital

Exclusion Criteria:

  • women less than 50 years old and 80 years old, bleeding tendency, stroke in the past
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00300833

Locations
Israel
Cardiovascular Division, The Baruch Padeh Medical Center, Poriya,
Tiberias, Israel, 15208
Magen David ,
Tiberias, Israel
Sponsors and Collaborators
The Baruch Padeh Medical Center, Poriya
Investigators
Study Chair: Menachem Naheer The Baruch Padeh Medicel Center, Poriya, Tiberias, Israel
  More Information

Responsible Party: Menachem Nahir, The baruch Padeh Medical center
ClinicalTrials.gov Identifier: NCT00300833     History of Changes
Other Study ID Numbers: Aggrastat in AMI.CTIL 
Study First Received: March 1, 2006
Last Updated: August 10, 2011
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Infarction
Myocardial Infarction
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Tirofiban
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors

ClinicalTrials.gov processed this record on December 02, 2016